Gross profit was US$1,487 thousand, or 27.4% of revenue, versus US$2,707 thousand, or 43.7%. The company attributed the lower margin primarily to adverse foreignExchange Ratefluctuations, revenue sharing expense, higher freight costs and tariffs. For the nine months, revenue was US$15,974 thousand versus US$16,953 thousand, …
The company noted that period comparisons are affected by changes in its reporting entity: the reverseRecapitalizationclosed on February 24, 2026, and Blackbox.io was deconsolidated on May 5, 2026. For the nine months, net revenues were US$1,923 thousand versus US$626 thousand, and gross margin was …
By stream,Advertisingtechnology and services revenue was US$11,169 thousand, with none a year earlier. Streaming and digital revenue was US$9,692 thousand versus US$9,558 thousand, media services revenue was US$3,110 thousand with none a year earlier, podcast and other revenue was US$1,067 thousand versus US$946 thousand, …
General and administrative expenses were US$4,048,851 versus US$3,474,059. The company said salaries and benefits in total decreased by US$144,794, withBonusexpense down US$1,865,131 because of a large one-time bonus in 2025 tied to its direct listing, and base salaries up US$1,497,896 to US$1,665,023 because of …
Other revenue was US$234 thousand versus US$606 thousand. The company said the 2026 amount consists of royalties recognized by Cyprium on net sales of ZYCUBO, and the prior-year amount of revenue from theSupplyof Amzeeq to Cutia.
The company said CARDAMYST (etripamil) nasal spray for the management of PSVT in the United States became available through U.S. retail pharmacies on January 26, 2026, and its national sales force was deployed in mid-February 2026. It said the license revenue came from a …
Property operating expenses were US$4,303 thousand versus US$7,987 thousand. Asset and property management fees to related parties were US$1,791 thousand versus US$1,682 thousand, and general and administrative expenses were US$2,884 thousand versus US$2,172 thousand.Depreciationand amortization was US$2,490 thousand versus US$3,545 thousand.
Research, development and patents expenses were US$1,248,796 versus US$1,582,975. The company attributed the US$0.4 million decrease primarily to lower MN-166 expenses relating to a pharmacokinetic study, a degenerative cervical myelopathy study and an ALS study. General and administrative expenses were US$1,867,277 versus US$1,806,070, which …
The company attributed the US$1.9 million increase primarily to US$1.5 million of higher external costs for CMC, clinical and toxicology studies, mainly a cardiac safety study of ARD-101, partly offset by lower clinical development costs after the voluntary pause and termination of the Phase …
The company tied the research increase to activity for the Phase 1 clinical trial of DA-1726, primarily higher direct DA-1726 development costs, partly offset by US$0.2 million of lower indirect consulting expenses.